Literature DB >> 34116820

Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.

Noa Krawczyk1, Arthur Robin Williams2, Brendan Saloner3, Magdalena Cerdá4.   

Abstract

BACKGROUND: Maintenance treatments with medications for opioid use disorder (MOUD) are highly effective at reducing overdose risk while patients remain in care. However, few patients initiate medication and retention remains a critical challenge across settings. Much remains to be learned about individual and structural factors that influence successful retention, especially among populations dispensed MOUD in outpatient settings.
METHODS: We examined individual and structural characteristics associated with MOUD treatment retention among a national sample of adults seeking MOUD treatment in outpatient substance use treatment settings using the 2017 Treatment Episode Dataset-Discharges (TEDS-D). The study assessed predictors of retention in MOUD using multivariate logistic regression and accelerated time failure models.
RESULTS: Of 130,300 episodes of MOUD treatment in outpatient settings, 36% involved a duration of care greater than six months. The strongest risk factors for treatment discontinuation by six months included being of younger age, ages 18-29 ((OR):0.52 [95%CI:0.50-0.54]) or 30-39 (OR:0.57 [95%CI:0.55-0.59); experiencing homelessness (OR: 0.70 [95%CI:0.66-0.73]); co-using methamphetamine (OR:0.48 [95%CI:0.45-0.51]); and being referred to treatment by a criminal justice source (OR:0.55 [95%CI:0.52-0.59) or by a school, employer, or community source (OR:0.71 [95%CI:0.66-0.76).
CONCLUSIONS: Improving retention in treatment is a pivotal stage in the OUD cascade of care and is critical to reducing overdose deaths. Efforts should prioritize interventions to improve retention among patients who are both prescribed and dispended MOUD, especially youth, people experiencing homelessness, polysubstance users, and people referred to care by the justice system who have especially short stays in care.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Discontinuation; Medication treatment; Opioid use disorder; Overdose; Retention

Mesh:

Year:  2021        PMID: 34116820      PMCID: PMC8197774          DOI: 10.1016/j.jsat.2021.108329

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  66 in total

Review 1.  Retention in medication-assisted treatment for opiate dependence: A systematic review.

Authors:  Christine Timko; Nicole R Schultz; Michael A Cucciare; Lisa Vittorio; Christina Garrison-Diehn
Journal:  J Addict Dis       Date:  2015-10-14

2.  Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample.

Authors:  Noa Krawczyk; Kenneth A Feder; Michael I Fingerhood; Brendan Saloner
Journal:  Drug Alcohol Depend       Date:  2017-07-11       Impact factor: 4.492

3.  Evaluating racial disparity in referral source and successful completion of substance abuse treatment.

Authors:  Ethan Sahker; Maisha N Toussaint; Marizen Ramirez; Saba R Ali; Stephan Arndt
Journal:  Addict Behav       Date:  2015-04-18       Impact factor: 3.913

4.  Development of a Cascade of Care for responding to the opioid epidemic.

Authors:  Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Frances R Levin; Mark Olfson
Journal:  Am J Drug Alcohol Abuse       Date:  2019-01-24       Impact factor: 3.829

5.  Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.

Authors:  Noa Krawczyk; Caroline E Picher; Kenneth A Feder; Brendan Saloner
Journal:  Health Aff (Millwood)       Date:  2017-12       Impact factor: 6.301

Review 6.  From opioid maintenance to abstinence: a literature review.

Authors:  Hege Kornør; Helge Waal
Journal:  Drug Alcohol Rev       Date:  2005-05

7.  Patient retention in mobile and fixed-site methadone maintenance treatment.

Authors:  L Greenfield; J V Brady; K J Besteman; A De Smet
Journal:  Drug Alcohol Depend       Date:  1996-10       Impact factor: 4.492

8.  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.

Authors:  Hillary Samples; Arthur Robin Williams; Mark Olfson; Stephen Crystal
Journal:  J Subst Abuse Treat       Date:  2018-09-07

9.  Distance traveled and cross-state commuting to opioid treatment programs in the United States.

Authors:  Andrew Rosenblum; Charles M Cleland; Chunki Fong; Deborah J Kayman; Barbara Tempalski; Mark Parrino
Journal:  J Environ Public Health       Date:  2011-07-06

10.  Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017.

Authors:  Lawrence Scholl; Puja Seth; Mbabazi Kariisa; Nana Wilson; Grant Baldwin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-04       Impact factor: 17.586

View more
  7 in total

1.  A qualitative examination of recent increases in methamphetamine use in a cohort of rural people who use drugs.

Authors:  Elizabeth R Hansen; Shelby Carvalho; Madelyn McDonald; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2021-10-28       Impact factor: 4.492

2.  Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder.

Authors:  Madeline C Frost; Julie E Richards; John R Blosnich; Eric J Hawkins; Judith I Tsui; E Jennifer Edelman; Emily C Williams
Journal:  Drug Alcohol Depend       Date:  2022-06-03       Impact factor: 4.852

3.  X-Waiver Exemption in the Treatment of Opioid Use Disorder.

Authors:  Riley D Shearer; Becky R Ford; Benjamin A Howell
Journal:  JAMA       Date:  2021-08-03       Impact factor: 157.335

4.  Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.

Authors:  Breanne E Biondi; Brent Vander Wyk; Esther F Schlossberg; Albert Shaw; Sandra A Springer
Journal:  Addict Sci Clin Pract       Date:  2022-03-07

5.  Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.

Authors:  Pia M Mauro; Sarah Gutkind; Erin M Annunziato; Hillary Samples
Journal:  JAMA Netw Open       Date:  2022-03-01

6.  Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection.

Authors:  Anthony J Eller; Elizabeth E DiDomizio; Lynn M Madden; Jennifer D Oliva; Frederick L Altice; Kimberly A Johnson
Journal:  Ann Med       Date:  2022-07-01       Impact factor: 5.348

7.  Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia.

Authors:  Antoine Chaillon; Chrianna Bharat; Jack Stone; Nicola Jones; Louisa Degenhardt; Sarah Larney; Michael Farrell; Peter Vickerman; Matthew Hickman; Natasha K Martin; Annick Bórquez
Journal:  Addiction       Date:  2021-12-04       Impact factor: 7.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.